- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05112003
Translingual Neurostimulation for the Virtual Treatment of Post-Traumatic Stress Disorder: A Feasibility Pilot
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3V 0C6
- Centre for Neurology Studies
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female, at least 19 years of age or older
- A score of 33 or more on the Posttraumatic Stress Disorder Checklist (PCL-5)
- PTSD symptom duration of ≥ 12 months
- Stable dose of any medications for the last three months, with no changes anticipated for the duration of the study
- Adequate support at home (e.g., family member or caregiver) to ensure assistance in seeking access to help if needed
- Able to understand the informed consent form, study procedures and willing to participate in study
- Currently has a primary care provider
Exclusion Criteria:
- History of substance dependence or abuse (within the last 3 months)
- Unstable psychosocial settings (homelessness, lack of support at home)
- Moderate to high risk of suicidal ideation or behaviour as measured by the Columbia Suicide Severity Rating Scale (C-SSRS)
- Current diagnosis of severe anxiety (or score of ≥15 on the GAD-7), severe depression (or score of ≥20 on the PHQ-9), schizophrenia or bipolar disorder
- Use of medications for PTSD within the last 6 weeks
- History of other major neurological disorder (brain cancer, dementia, multiple sclerosis, stroke)
- Detection of mild cognitive impairment (mini-ACE score of ≤ 25)
- Diagnosed epilepsy or history of seizures
- Not proficient in English
- Recent (within last 2 years) acquired brain injury
- Exposed to an investigational drug or device 30 days prior to starting the study, or concurrent use of an investigational drug or device while enrolled in the study
- If female and of child-bearing potential: pregnant, suspected or planning to become pregnant or breast-feeding
Contraindicated for the NeuroCatchTM Platform, including:
13.1. Requires the use of hearing aids or a cochlear implant 13.2. Diagnosed with tinnitus that is currently active 13.3. Has temporary damage to earing (e.g. punctured ear drum) 13.4. Unable to detect a 740Hz tone played at 85dB in both ears. 13.5. Implanted pacemaker or implanted electrical stimulators 13.6. Metal or plastic implants in the skull, excluding dental/facial implants 13.7. Unhealthy scalp (apparent open wounds and/or bruised or weakened skin) 13.8. Previous exposure to the NeuroCatch™ Platform audio sequences in the last 3 months
- Contraindicated for PoNSTM use, including:
14.1. Current disease or sensitivity of the oral cavity 14.2. History of oral cancer 14.3. Oral surgery within three months of screening 14.4. Oral cavity piercings that could interfere with PoNSTM use 14.5. Sensitivity to Nickel, Copper, or Gold 14.6. Currently enrolled in a PoNSTM treatment program or use of the PoNSTM device in the last 5 weeks 14.7. History of penetrating brain injuries 14.8. History of neurodegenerative diseases 14.9. Chronic infectious disease 14.10. Unmanaged hypertension 14.11. Diabetes 14.12. History of seizures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TLNS
Translingual neurostimulation will be paired with breathing and awareness training prior to CPT sessions
|
The device will be placed into and held in the participant's mouth for 20 minutes while the participant undergoes breathing and awareness training
|
No Intervention: Control
No TLNS
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants screened who are eligible
Time Frame: Baseline to week 6
|
Reach (RE-AIM framework)
|
Baseline to week 6
|
Clinician-rated symptom severity as measured by CAPS
Time Frame: Change from baseline to week 6
|
Effectiveness (RE-AIM framework)
|
Change from baseline to week 6
|
Participant rated symptom severity as measured by the PCL-5
Time Frame: Change from baseline to week 6
|
Effectiveness (RE-AIM framework)
|
Change from baseline to week 6
|
Proportion of therapy visits completed
Time Frame: Baseline to Week 6
|
Adoption (RE-AIM framework)
|
Baseline to Week 6
|
Ease of protocol administration
Time Frame: Baseline to week 6
|
Adoption (RE-AIM framework); 5-point Likert scale for participants and therapists
|
Baseline to week 6
|
Qualitative report of barriers and facilitators
Time Frame: Baseline to week 6
|
Implementation (RE-AIM framework)
|
Baseline to week 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Electroencephalography (EEG)
Time Frame: Change from baseline to week 6
|
Using the NeuroCatchTM Platform - EEG amplitudes
|
Change from baseline to week 6
|
Electroencephalography (EEG)
Time Frame: Change from baseline to week 6
|
Using the NeuroCatchTM Platform - EEG latencies
|
Change from baseline to week 6
|
Generalized Anxiety Disorder 7-item (GAD-7)
Time Frame: Change from baseline to week 6
|
Anxiety symptom severity self-report measure
|
Change from baseline to week 6
|
Patient Health Questionnaire (PHQ-9)
Time Frame: Change from baseline to week 6
|
Depression symptom severity self-report measure
|
Change from baseline to week 6
|
Brief Inventory of Psychosocial Functioning (B-IPF)
Time Frame: Change from baseline to week 6
|
PTSD-related functional impairment in the prior 30 days
|
Change from baseline to week 6
|
Meaning in Life Questionnaire (MLQ)
Time Frame: Change from baseline to week 6
|
Assesses two dimensions of meaning in life using 10 items rated on a seven-point scale
|
Change from baseline to week 6
|
Time from inciting event
Time Frame: Baseline
|
Time since traumatic event (years)
|
Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HTC_PTSD_001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post-traumatic Stress Disorder
-
University of California, Los AngelesDefense Advanced Research Projects Agency; Defense Group, Inc.CompletedPost-traumatic Stress Disorder | Post-Traumatic Stress Disorder, ChronicUnited States
-
Weill Medical College of Cornell UniversityCompletedPost-traumatic Stress Disorder | Complex Post-Traumatic Stress DisorderUnited States
-
University of California, Los AngelesRecruitingPost-traumatic Stress Disorder | Post-Traumatic Stress Disorder in ChildrenUnited States
-
University of UtahEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedPost-Traumatic Stress Disorder in Children | Post-Traumatic Stress Disorder in AdolescenceUnited States
-
University of ZurichCompletedPost Traumatic Stress Disorder (PTSD) | Complex Post-Traumatic Stress Disorder (CPTSD)Switzerland
-
University of NottinghamNottinghamshire Healthcare NHS Trust; Lincolnshire Partnership NHS Foundation...CompletedDomestic Violence | Trauma, Psychological | Post-Traumatic Stress Disorder in Children | Narrative Exposure Therapy | Post-Traumatic Stress Disorder in Adolescence | Post-Traumatic Stress Disorder ComplexUnited Kingdom
-
Praxis Precision MedicinesTerminatedStress Disorders, Post-Traumatic | Trauma and Stressor Related Disorders | Post Traumatic Stress Disorder | Stress Disorder | Post-traumatic Stress Disorder | Mental DisorderUnited States
-
University Hospital, LilleNot yet recruiting
-
Steinn SteingrimssonRecruiting
-
Direction Centrale du Service de Santé des ArméesRecruitingPost-traumatic Stress DisorderFrance
Clinical Trials on Translingual neurostimulation
-
University of SaskatchewanMemorial University of NewfoundlandEnrolling by invitation
-
Assistance Publique - Hôpitaux de ParisInstitut National de Recherche en Informatique et en Automatique; Centre Bouffard... and other collaboratorsCompleted
-
Massachusetts General HospitalBoston University; National Institute of Neurological Disorders and Stroke...Recruiting
-
Emory UniversityNational Institute of Mental Health (NIMH)Recruiting
-
Hillel Yaffe Medical CenterUnknown
-
Centre Bouffard Vercelli - USSAPInstitut National de Recherche en Informatique et en Automatique; NEURINNOVCompleted
-
University Hospital, GrenobleMinistry of Health, FranceTerminatedEpilepsy | Drug ResistantFrance
-
Klaus MartinyTechnical University of Denmark; OptoCeuticsNot yet recruitingMajor Depressive Disorder | Treatment Resistant DepressionDenmark
-
The University of Texas Medical Branch, GalvestonNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingUnderstanding the Effects of Transcutaneous Auricular Neurostimulation for Treatment of Chronic PainAnalgesia | Opioid WithdrawalUnited States